At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Ofatumumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
In Brief
A Phase 2 clinical trial evaluating Ofatumumab for Waldenstrom Macroglobulinaemia. Completed, enrolled 37 participants across 7 sites.
Detailed Summary
Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of ofatumumab is being initiated in patients with Waldenstrom's Macroglobulinemia (WM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom Macroglobulinaemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartMar 2009
Primary CompletionJun 2011
Study CompletionFeb 2014
TodayJul 2026
First PostedDec 19, 2008
Enrollment StartMar 1, 2009
Primary CompletionJun 1, 2011
Study CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.5 years ago
Interventions
Ofatumumabbiological
Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.